Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Dose-Finding Study of RMC-035 in High-Risk Open-Chest Cardiac Surgery
2024-510658-28-00Phase 2Completed
- Sponsor
- Guard Therapeutics
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of RMC-035 in acute kidney failure (AKF) (3 arms), sponsored by Guard Therapeutics. Primary endpoint: Change from baseline in eGFR based on serum creatinine at Day 90 (pooled low and high dose levels). Started Aug 2024; status: completed.
02
Drugs
RMC-035
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on 2024-510658-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510658-28-00.